Excellence in clinical research from A to Z

Scroll down ⇩

About us

AtoZ-CRO GmbH is a full-service clinical research organisation (CRO) located in Overath near Cologne, Germany, with over 30 years of experience in clinical development and clinical study management. As a specialist for Germany, Europe, the US, and India, AtoZ-CRO offers a broad range of professional services and partner solutions for international clinical studies with pharmaceuticals and medical devices.


From its head office located in Overath, Germany, AtoZ-CRO manages and coordinates clinical studies of phase 0 through phase IV for national and international clients. The company forms a team of 35 highly experienced and dedicated industry professionals and medical specialists ensuring high standards in clinical study management. AtoZ-CRO is affiliated with a leading initiator of phase I studies in Warsaw, Poland.


Based on the company’s long-established international experience in clinical trial management and cooperation with high-rated business partners, AtoZ-CRO is proud to offer a broad range of services covering all clinical research needs, in particular for small and mid-sized pharmaceutical, biotech, and medical device companies.

Clinical Studies 

Contact us

Clinical Studies

Clinical Studies Phases 0 – IV

  • Planning of clinical studies
  • Preparation of study protocols
  • Design and implementation of CRFs (case report forms) and eCRFs
  • Processing of applications for ethical votes and permissions (e.g. CTA, IND)
  • Regulatory affairs issues
  • Legal EU representative

Other services

  • Monitoring
  • Post-marketing studies

-  NIS

-  PASS

-  Epidemiology

  • Pharmacovigilance
  • Biometry
  • Medical Writing and Translations

About us

Contact us

Contact us

AtoZ-CRO GmbH

Hauptstr. 77
51491 Overath
Tel: 02206 95 99 0
Fax: 02206 820 63
Email: info@atoz-cro.de
www.atoz-cro.de

Business Development

Alexa Foltin-Mertgen, M.Sc.
Email: a.foltin-mertgen@atoz-cro.de

Back to top ⇧

Go to article: Home | A new era of buyers clubsGo to article: TSS ABGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Capsugel Company InsightGo to article: The pharma industry briefingGo to article: ICCI Company InsightGo to article: ICCIGo to article: Corbion PuracGo to article: Real world data: improving clinical trial outcomesGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: Understanding allergic reactions: chronicling the work of Dr Teruko IshizakaGo to article: Scandinavian HealthGo to article: Moehs Iberica SLGo to article: Swiss WorldCargoGo to article: Buyers’ clubs: the first step toward universal UK access to Orkambi?Go to article: TSS Company InsightGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CRO GmbHGo to article: Prescription dread: measuring psychiatric drugs against the alternativesGo to article: BEAGo to article: ZenatekGo to article: PfanstiehlGo to article: Herd health: agriculture’s role in the global AMR crisisGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Hapa Company InsightGo to article: ConcePTION: tackling the unknowns of medication in pregnancyGo to article: AEB Company Insight Go to article: AEBGo to article: Pfeiffer VacuumGo to article: From start-ups to the SIX Swiss Exchange – a Swiss success storyGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Cancer drug discovery: unravelling the mysteries of halichondrinGo to article: Centaur Clinical | Company InsightGo to article: IDMP is back: what next?Go to article: Charles Ischi Go to article: Adhesives ResearchGo to article: Emirates SkyCargoGo to article: Global labelling management: why does it continue to cause problems?Go to article: B&W TekGo to article: EventsGo to article: Dali Medical devicesGo to article: Spirax Sarco Company InsightGo to article: Spirax SarcoGo to article: Centaur ClinicalGo to article: Next issueGo to article: AralabGo to article: Baxter